The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1520
ISSUE1520
May 8, 2017
Drugs for Allergic Disorders
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Allergic Disorders
May 8, 2017 (Issue: 1520)
Allergic rhinitis can be classified as seasonal,
perennial, or episodic. It is often associated with
allergic conjunctivitis, rhinosinusitis, and asthma. H1-ANTIHISTAMINES — Oral – Oral second-generation
H1-antihistamines are the preferred...more
- MD Seidman et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg 2015; 152:197.
- GK Scadding. Optimal management of allergic rhinitis. Arch Dis Child 2015; 100:576.
- FE Simons and KJ Simons. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011; 128:1139.
- MK Church et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010; 65:459.
- MP McKay and L Groff. 23 years of toxicology testing fatally injured pilots: implications for aviation and other modes of transportation. Accid Anal Prev 2016; 90:108.
- Y Katayose et al. Carryover effect on next-day sleepiness and psychomotor performance of nighttime administered antihistaminic drugs: a randomized controlled trial. Hum Psychopharmacol 2012; 27:428.
- SL Gray et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175:401.
- BM Prenner. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. J Asthma Allergy 2016; 9:135.
- P Ratner et al. Efficacy of daily intranasal fluticasone propionate on ocular symptoms associated with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2015; 114:141.
- OTC fluticasone furoate nasal spray (Flonase Sensimist) for allergic rhinitis. Med Lett Drugs Ther 2017; 59:e70.
- A Nayak and RB Langdon. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007; 67:887.
- In brief: Oral phenylephrine for nasal congestion. Med Lett Drugs Ther 2015; 57:174.
- E Mehuys et al. Self-medication in persistent rhinitis: overuse of decongestants in half of the patients. J Allergy Clin Immunol Pract 2014; 2:313.
- B Lange et al. Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005; 95:272.
- S Tsabouri et al. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract 2014; 2:332.
- F Etwel et al. The risk of adverse pregnancy outcome after first trimester exposure to H1-antihistamines: a systematic review and meta-analysis. Drug Saf 2017; 40:121.
- I Pali-Schöll et al. Allergic diseases and asthma in pregnancy, a secondary publication. World Allergy Organ J 2017; 10:10.
- M Shaker and E Salcone. An update on ocular allergy. Curr Opin Allergy Clin Immunol 2016; 16:505.
- Alcaftadine (Lastacaft) for allergic conjunctivitis. Med Lett Drugs Ther 2011; 53:19.
- M Castillo et al. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev 2015;6:CD009566.
- JD Sheppard et al. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther 2016; 33:532.
- KH Hsu and A Chauhan. Rapid and selective removal of preservative from ophthalmic formulations during eyedrops instillation. Eur J Pharm Biopharm 2015; 97:30.
- EJ van Zuuren et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev 2017; 2:CD012119.
- DJ Margolis et al. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol 2015; 151:594.
- Crisaborole (Eucrisa) for atopic dermatitis. Med Lett Drugs Ther 2017; 59:34.
- AS Paller et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016; 75:494.
- L Schneider et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131:295.
- Dupilumab (Dupixent) for moderate to severe atopic dermatitis. Med Lett Drugs Ther 2017; 59:64.
- EL Simpson et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335.
- A Blauvelt et al. Long-term management of moderate-to-severe atopic dermatitis (AD) with dupilumab and concomitant topical corticosteroids (TCS): a 1-year, randomized, placebo-controlled phase 3 trial (CHRONOS). Presented at the 75th American Academy of Dermatology (AAD) Annual Meeting, Orlando, FL, March 3-7, 2017. Abstract 5267.
- R Sidbury et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71:327.
- E Roekevisch et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014; 133:429.
- G Deza and AM Giménez-Arnau. Itch in urticaria management. Curr Probl Dermatol 2016; 50:77.
- T Zuberbier et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69:868.
- Omalizumab (Xolair) for chronic urticaria. Med Lett Drugs Ther 2013; 55:43.
- ZT Zhao et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016; 137:1742.
- JL Zazzali et al. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Ann Allergy Asthma Immunol 2016; 117:370.
- P Staubach et al. Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy 2016; 71:1135.
- DR Doshi and MM Weinberger. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol 2009; 26:409.
- M Morgan et al. Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol Pract 2014; 2:601.
- LA Beck et al. A review of international recommendations for the diagnosis and management of chronic urticaria. Acta Derm Venereol 2017; 97:149.
- M Maurer et al. Current and future therapies for treating chronic spontaneous urticaria. Expert Opin Pharmacother 2016; 17:1131.
- Sublingual immunotherapy for allergic rhinitis. Med Lett Drugs Ther 2014; 56:47.
- SR Durham and M Penagos. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol 2016; 137:339.
- TG Epstein et al. Current evidence on safety and practical considerations for administration of sublingual allergen immunotherapy (SLIT) in the United States. J Allergy Clin Immunol Pract 2017; 5:34.
- RA Wood. Food allergen immunotherapy: current status and prospects for the future. J Allergy Clin Immunol 2016; 137:973.
- S Lee et al. Trends, characteristics, and incidence of anaphylaxis in 2001-2010: a population-based study. J Allergy Clin Immunol 2017; 139:182.
- MM McNeil et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016; 137:868.
- P Lieberman et al. Anaphylaxis – a practice parameter update 2015. Ann Allergy Asthma Immunol 2015; 115:341.
- TB Casale and AW Burks. Hymenoptera-sting hypersensitivity. N Engl J Med 2014; 370:1432.
- P Lieberman and FE Simons. Anaphylaxis and cardiovascular disease: therapeutic dilemmas. Clin Exp Allergy 2015; 45:1288.
- ES Edwards et al. Epinephrine 0.3 mg bioavailability following a single injection with a novel epinephrine auto-injector, e-cue, in healthy adults, with reference to a single injection using EpiPen 0.3 mg. J Allergy Clin Immunol 2012; 129:AB179.
- M Anshien et al. Unintentional epinephrine auto-injector injuries: a national poison center observational study. Am J Ther 2016 Nov 24 (epub).
- Auvi-Q epinephrine auto-injector returns. Med Lett Drugs Ther 2017; 59:33.
- SH Sicherer et al. Epinephrine for first-aid management of anaphylaxis. Pediatrics 2017; 139:e20164006.
- DB Golden. Large local reactions to insect stings. J Allergy Clin Immunol Pract 2015; 3:331.
- Odactra - sublingual immunotherapy for house dust mite-induced allergic rhinitis. Med Lett Drugs Ther 2018; 60:37.
- In brief: neuropsychiatric events with montelukast. Med Lett Drugs Ther 2020; 62:65.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Allergic Disorders
Article code: 1520a
Article code: 1520a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.